Cargando…
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
Finding targetable gene fusions can expand the limited treatment options in radioactive iodine-refractory (RAI-r) thyroid cancer. To that end, we established a novel cell line ‘JVE404’ derived from an advanced RAI-r papillary thyroid cancer (PTC) patient, harboring an EML4-ALK gene fusion variant 3...
Autores principales: | Aydemirli, Mehtap Derya, van Eendenburg, Jaap D H, van Wezel, Tom, Oosting, Jan, Corver, Willem E, Kapiteijn, Ellen, Morreau, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183637/ https://www.ncbi.nlm.nih.gov/pubmed/33878728 http://dx.doi.org/10.1530/ERC-20-0436 |
Ejemplares similares
-
Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2019) -
Yield and costs of molecular diagnostics on thyroid cytology slides in the Netherlands, adapting the Bethesda classification
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2021) -
Metabolic reprogramming related to whole-chromosome instability in models for Hürthle cell carcinoma
por: Addie, Ruben D., et al.
Publicado: (2020) -
Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines
por: Boot, Arnoud, et al.
Publicado: (2017) -
A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature
por: Aydemirli, M. D., et al.
Publicado: (2019)